Organic Active Ingredients TRIZ Cases

Senolytic agents eliminate p16Ink4a-positive cells from plaques, reducing plaque burden and stabilizing lesions against rupture.

Deoxygenated water and oxygen-scavenging agents protect superoxide dismutase from reactive oxygen species degradation during storage.

Segments immune checkpoint inhibition using IDO1 and PD-L1 peptides alongside nivolumab to reverse the immunosuppressive tumor microenvironment.

2-thioxothiazolidine-4-one derivatives modulate protein assembly to prevent aggregate formation.

A dielectric liquid medium enables electrostatic attraction between oppositely charged reactant bodies to drive chemical reactions.

Segmented step-up dosing of mosunetuzumab reduces cytokine release syndrome while maintaining high objective response rates in elderly lymphoma patients.

Administering oral EGFR ligands mimics natural breast milk patterns to control Th2 responses, preventing necrotizing enterocolitis and sepsis.

A self-emulsifying cannabinoid system forms stable nanoemulsions with controlled particle sizes.

Adding a de-ionizing agent to the polyethylene glycol solvent prevents ester formation that reduces drug availability in softgel capsules.

LMTX compounds overcome energy barriers for oxygen binding to hemoglobin, raising blood oxygen saturation without methaemoglobin elevation.

Targeting MCM complex assembly prevents nuclear localization and induces apoptosis in cancer cells while sparing normal cells with intact checkpoints.

Macrocyclic compounds inhibit complement Factor D to sustain therapeutic efficacy while avoiding side effects from short half-life existing inhibitors.

Albumin-carbonate aqueous system dissolves bilirubin at pH 11-12, eliminating organic solvents and preventing photo-degradation.

Macrocyclic lactones disrupt ATP signaling pathways to kill cancer cells resistant to conventional therapies.

Chaperone-mediated autophagy activators expand hematopoietic stem cell populations while maintaining undifferentiated states.

Topical L-epinephrine compositions induce vasoconstriction to lower tissue oxygen levels, protecting healthy cells from chemotherapy and radiotherapy damage.

Increasing histidine to 0.3 g per meal overcomes flavor limits while improving biorhythm without side effects.

Co-administering DDR and GDF15 inhibitors blocks resistance mechanisms, restoring cancer cell sensitivity to treatment.

Hybrid promoters enable stable therapeutic gene integration to correct genetic defects in glycogen storage diseases.

Combining anthranilic acid amides with cooling agents achieves significant itching relief at low concentrations, avoiding formulation technology issues.

Novel cyclic dinucleotides activate the STING pathway to induce endogenous cytokines, overcoming short half-life limitations of direct administration.

A cholinergic neuron-specific enhancer drives targeted therapeutic polypeptide expression in spinal motor neurons.

Benzimidazole derivatives inhibit KCa3.1 channels to reduce albuminuria and prevent podocyte injury in kidney disease treatment.

Processed human umbilical cord filtrate replaces enzymatic collagenase to dissolve plaques while avoiding erectile dysfunction and hematoma risks.

Precise pH control during synthesis yields high-purity complex acidic salts with defined hydration levels, resolving composition variability issues.

An automated digital platform reduces treatment delivery complexity by enabling independent assessment of drinking patterns and craving control.

A brain health supplement composition combines phosphatidylserine, Ginkgo biloba extract, and Bacopa monnieri extract to enhance cognitive function.

T1AM and related substances induce muscular atrophy by activating protein degradation pathways, replacing invasive denervation models.

Measuring LCK nucleic acid and protein activity levels predicts dasatinib and ponatinib response in T-ALL patients lacking ABL-rearrangements.

A controlled release pharmaceutical composition uses a lipophilic excipient system to sustain tolperisone hydrochloride delivery.

Inhibiting MNK1 and MNK2 in genetically modified T cells promotes central memory subset expansion.

Modifying oral microbiome composition using beneficial bacteria and antibacterial strips prevents pathogenic transmission to the brain.

Amino derivatives of dehydroleucodine improve water solubility and bioavailability to inhibit cancer cell growth without compromising cytotoxic efficacy.

Selective JAK1/JAK2 inhibition treats prurigo nodularis while reducing systemic toxicity.

Ethylcellulose binder provides mechanical strength to rapidly disintegrating tablets without retarding breakup.

Intranasal NAC bypasses the blood-brain barrier to restore brain glutathione, reducing SARS-CoV-2 severity in vulnerable populations.

Novel heterocyclic compounds block CXCR3 receptor activity to mitigate autoimmune responses.

Replacing pressurized kettles with atmospheric gas sparging reduces manufacturing costs and impurity risks while maintaining high reaction yields.

Administers anti-inflammatory adjuncts alongside exon skipping therapy to reduce muscle tissue inflammation without hindering oligonucleotide uptake.

Segmenting bilirubin into synthesizable precursors eliminates complex separation steps required for animal extraction.

Controlled precipitation prevents secondary agglomeration of ezetimibe particles, maintaining high specific surface area for improved bioavailability.

Targeting Shn2 and Shn3 resolves the trade-off between precise bone density modulation and uncontrolled growth in specific regions.

Tangential flow filtration isolates extracellular vesicles carrying neprilysin and miR-29a/b to reduce amyloid-beta deposition in Alzheimer's disease.

Complementary oligonucleotides target miR-214 to delay fibrosis onset and improve organ function.

Hydraulic loading of a gel vector into a porous ceramic matrix enables controlled release of antibiotics, reducing infection risk in bone cancer implants.

ST2 and Reg3α plasma biomarkers identify severe GVHD risk before symptoms, preventing opportunistic infections from universal immunosuppression.

Targeting conserved hemagglutinin stems enables broad neutralization across multiple influenza subtypes.

Segmented ingestible devices deliver TLR modulators directly to disease sites, bypassing stomach degradation to improve bioavailability.

Riboside derivatives increase intracellular NAD+ levels in skin cells through enhanced lipophilicity.

Benzothiazolyl urea compounds induce ubiquitination and degradation of SUMO1 protein to inhibit cancer cell growth.

Allosteric binding to PCSK9 reduces LDL cholesterol levels while avoiding non-specific inhibition common in small molecule assays.

Integrating a replacement cap inside the package body eliminates separate packaging, preventing air introduction and contamination during dosage adjustment.

Microwave-synthesized glucosidic astaxanthin normalizes membrane capacitance to resolve abnormal cellular functions in cancer treatment.

Oral CCR2 antagonists deplete tumor-associated macrophages and expand CD8+ T cells in cutaneous T-cell lymphoma models.

Aqueous gel with synthetic peptides enables transdermal hormone supplementation to deliver active compounds through the skin barrier.

Methanesulfonate or hydrochloride salts of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine form stable crystals.

Eutectic mixture in soft gel capsules stabilizes serum levels, reducing dosing frequency and liver damage risks.

Quinazoline-based compounds improve aqueous solubility for local nasal delivery, resolving systemic side effects while maintaining anti-inflammatory efficacy.

Epirubicin-conjugated block copolymer micelles encapsulate staurosporine within a hydrophobic core to target resistant tumors.

Small molecule compounds modulate inflammatory bowel disease markers through targeted pathway intervention.

Sequential fatty acid administration boosts 8-hydroxyoctanoic acid levels to overcome treatment resistance in COX-2 over-expressing diseases.

Modifying guide RNA nucleotides resolves the trade-off between high cleavage efficiency and specificity, preventing off-target cuts.

Human intravenous immunoglobulin combined with steroids treats Bell's palsy to enhance nerve recovery speed.

Antisense oligonucleotides delivered via viral vectors inhibit betaAPP synthesis in the choroid plexus.

Replacing hydrogen with deuterium in pyrimidine structures enhances metabolic stability and CNS penetration for safer hMrgX1-mediated pain relief.

Spinach-derived glycosides resolve inadequate treatment outcomes by significantly inhibiting excessive airway mucus secretion and cytokine production.

Sulfasalazine derivatives inhibit PMP22 protein expression to reverse demyelination and improve neurological function in Charcot-Marie-Tooth disease models.

Allogeneic oligodendrocyte progenitor cells engraft at spinal cord injury sites to promote neural repair and axonal outgrowth.

Hydrophilic polyethylene oxide matrices control ketamine dissolution rates to minimize dissociative side effects while maintaining therapeutic efficacy.

A nutraceutical formulation combining docosahexaenoic acid and fisetin stabilizes microtubules to protect cognitive function.

A crystalline form of a bromodomain inhibitor acts as a BRD4 inhibitor for solid dosage forms.

Reversing Na/K-ATPase inhibition reduces intestinal glucose and sodium absorption, addressing obesity-related metabolic deregulation.

Segmentation of the synthesis into two steps reduces time and complexity, while parameter changes identify stable crystal form C for commercial production.

Chromene derivatives with heteroaromatic substituents resolve gastrointestinal toxicity trade-offs while maintaining high analgesic efficacy.

Micronized liposome powder encapsulates electrolytes to bypass digestive issues and improve skin absorption.

Substituted heterocyclic compounds bind tubulin at the colchicine site to inhibit tumor cell growth.

Statin-loaded stem cells migrate to ischemic tissue, releasing nanoparticles that promote neovascularization without requiring invasive local injection.

Fluorinated antibacterial compounds treat multi-drug resistant infections while reducing inflammation-inducing cytokine levels.

Compounds of Formulas I-V activate wild type and mutant PKR enzymes, improving red blood cell energy metabolism and reducing hemolytic anemia severity.

Specific binding moieties isolate bioactive peptides from edible bird's nest, resolving low bioavailability and allergenicity in traditional processing.

Alanylglutamine dipeptide boosts exercise time to exhaustion independently of plasma concentrations, bypassing the energy costs of traditional training.

Quantifying specific gene expression levels to tailor folate administration, resolving variable efficacy and toxicity in cancer treatment.

Selecting low-viscosity cellulose ethers prevents storage-induced thickening, enabling higher drug concentrations without refrigeration.

Measuring BPTF expression levels overcomes resistance to BRAF inhibitors by guiding shRNA-mediated suppression or bromodomain inhibitor therapy.

CRISPR-Cas9 reduces NRF2 expression to overcome drug resistance and enhance chemotherapy effectiveness.

Nicotinamide alleviates summer itch and skin damage in horses without corticosteroid-induced laminitis risk.

SHIP inhibitors expand lysosomal compartments to activate microglial phagocytosis, clearing beta-amyloid peptides in Alzheimer's disease.

Hydrophobic colloidal silica adsorbs low-melting drugs to prevent delamination and cold flow in transdermal patches.

A photochemical process uses supercritical carbon dioxide to dissolve 7-dehydrocholesterol for efficient Vitamin D3 synthesis.

HS8 mediates FGF2 signaling to expand human mesenchymal stem cells, resolving the trade-off between increased cell numbers and loss of multipotency.